Core Viewpoint - The company, Zhejiang Haixiang Pharmaceutical Co., Ltd., is actively involved in investment activities and has recently made significant moves regarding its employee stock ownership plan and investments in other firms, which may impact investor confidence and stock performance. Group 1: Stock Performance and Market Activity - As of January 19, 2026, Haixiang Pharmaceutical's stock closed at 6.54 yuan, reflecting a 0.31% increase, with a turnover rate of 1.22% and a trading volume of 196,700 shares, amounting to a transaction value of 128 million yuan [1] - On January 19, the net inflow of funds from major investors was 7.80 million yuan, while speculative funds saw a net inflow of 9.57 million yuan, contrasted by a net outflow of 17.37 million yuan from retail investors [2][4] Group 2: Corporate Announcements and Investments - The company announced its participation in establishing the Hangzhou Fuhong Equity Investment Partnership with an investment of 100 million yuan, specifically targeting non-listed shares of Fuhong Hanlin [3] - As of January 19, 2026, the company received notification that Fuhong Hanlin has been registered with the China Securities Regulatory Commission, and some of its shareholders' domestic unlisted shares will be converted to H-shares for listing on the Hong Kong Stock Exchange, pending further regulatory procedures [3][4]

证券代码：002099 证券简称：海翔药业 公告编号：2026-003 浙江海翔药业股份有限公司 关于参投合伙企业投资复宏汉霖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 浙江海翔药业股份有限公司 董 事 会 浙江海翔药业股份有限公司（以下简称"公司"）第六届董事会第十二次会 议审议《关于参与设立合伙企业投资复宏汉霖的议案》，同意公司出资 1 亿元人 民币，参与发起设立台州富宏股权合伙企业（有限合伙）【现已更名："杭州复 宏股权投资合伙企业（有限合伙）"，以下简称"合伙企业"】。该合伙企业为 专项基金，专项投资于上海复宏汉霖生物技术股份有限公司（证券简称："复宏 汉霖"，证券代码：02696）的非上市股份。具体内容详见巨潮资讯网及 2021 年 6 月 5 日在《证券时报》《中国证券报》《上海证券报》《证券日报》刊登的 《关于参与设立合伙企业投资复宏汉霖的公告》（公告编号：2021-023）。 二、本次投资进展情况 2026 年 1 月 19 日，公司收到合伙企业出具的《2026 年 1 月项目运作临时管 理报告》，告知复宏汉霖于近日 ...

Commercial Aerospace - Lichong Group supplies high-end aluminum-based functional intermediate alloys for the commercial aerospace sector [1] Humanoid Robots - Shiyun Circuit has secured a new generation humanoid robot project [1] AI Applications - Longkun Technology's AI biopharmaceutical project is currently in the pre-clinical stage [1] - Bona Film Group has officially launched AI tools "Bole One-Click AI Short Drama" and "Bole Round Table" [1] Other Developments - CATL is advancing high energy density battery technologies, including condensed and solid-state batteries, for aviation applications [1] - Haixiang Pharmaceutical's invested Yuxin Fund holds a 1.352% stake in Tianbing Technology [1] - Zhejiang Fu Holdings reports that rising commodity prices have a positive impact on the company's performance [1] - Meiansen has no collaboration with the European Dorgerberg Steel Plant [1] - Zhite New Materials has no business or revenue related to AI applications, quantum technology, or artificial intelligence [1] - Woge Optoelectronics has completed small batch sample delivery of 1.6T optical module glass-based substrates [1]

Group 1 - The core viewpoint of the article is that Haixiang Pharmaceutical (002099) has invested in the Yuxin Fund, which holds stakes in Tianbing Technology and Aisida Aerospace, with ownership percentages of 1.352% and 2.83% respectively [1] - Both Tianbing Technology and Aisida Aerospace have initiated IPO guidance, indicating potential future public offerings [1]

Group 1 - The core point of the article is that Haixiang Pharmaceutical (002099) reported a total of 31,210 shareholders as of January 9, 2026 [1]

Group 1 - Weiteou signed a strategic cooperation agreement with Qiteng Robotics to focus on safety upgrades in high-risk industries, leveraging new materials and robotics [1] - Dongfang Caifu's subsidiary received approval from the CSRC to issue subordinate bonds totaling up to 20 billion yuan [2] - Haibo Zhongke's controlling shareholder plans to reduce holdings by up to 2.98% of the company's shares [3] Group 2 - Shengyang Technology's subsidiary FTA is expanding into the foreign satellite internet terminal business, which is still in the early commercialization stage [4] - Cangge Mining expects a net profit increase of 43.41%-53.1% for 2025, projecting a profit of 3.7-3.95 billion yuan [5] - Jinlongyu plans to invest approximately 1.2 billion yuan to build a production line for solid-state batteries with an annual capacity of 2 GWh [6] Group 3 - Shengda Resources intends to acquire a 55% stake in Guangxi Laibin Jinshi Mining for 269.5 million yuan [7] - Zhifei Biological's CA111 injection has entered Phase I clinical trials, targeting diabetes and weight loss treatment [8] - Qusleep Technology's specific shareholders plan to reduce their holdings by up to 2.58% of the company's shares [9] Group 4 - Innovation Medical's subsidiary has a product expected to generate revenue of 114,000 yuan in 2025 [11] - Blue Ocean Cursor noted that AI-driven revenue currently constitutes a small portion of overall revenue [12] - *ST Yanshi anticipates a loss for the 2025 fiscal year, with revenue expected to be below 300 million yuan [13] Group 5 - ST Yishite will lift risk warnings and change its stock name, resuming trading on January 14 [14] - Shaoyang Hydraulic clarified that its products do not directly serve commercial aerospace clients [15] - Boss Electric plans to invest 100 million yuan in Youte Smart Kitchen to deepen strategic cooperation [16] Group 6 - Guo An Da's controlling shareholder plans to reduce holdings by up to 3% of the company's shares [17] - *ST Mingjia has lifted the delisting risk warning following the completion of its restructuring plan [18] - Haixiang Pharmaceutical signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical [19] Group 7 - Palm Holdings plans to transfer stakes in two project companies for debt compensation, amounting to 258 million yuan [20] - Bohai Leasing's subsidiary Avolon is projected to have a fleet of 1,132 aircraft by the end of 2025 [21] - Zhenyou Technology reported that satellite internet revenue accounted for approximately 7.15% of total revenue in the first three quarters of 2025 [22] Group 8 - Blue Arrow Electronics intends to acquire at least 51% of Chengdu Xinyi Technology [23] - Shunhao Co. stated that its investment in Tianshu Chuangxin will have a minimal impact on its 2025 performance [24][25] - Baichuan Co.'s deputy general manager plans to reduce holdings by up to 0.65% of the company's shares [26] Group 9 - Zhewen Interconnect reported that its GEO business has not yet formed a mature profit model [27] - XW Communication's controlling shareholder plans to reduce holdings by up to 1% of the company's shares [28] - Electric Science Digital indicated that its satellite communication products are not its main business [29] Group 10 - Bojun Technology expects a net profit increase of 35%-65% for 2025, projecting a profit of 828-1,012 million yuan [30] - Rongchang Bio signed a licensing agreement for the RC148 drug with AbbVie, with an initial payment of 650 million USD [31] - Guoxin Technology's state investment fund plans to reduce holdings by up to 2.37% of the company's shares [32] Group 11 - Hengxuan Technology's controlling shareholder plans to reduce holdings by up to 3% of the company's shares [33][34] - *ST Chengchang announced a stock suspension for investigation due to abnormal trading [35] - Zhongji Xuchuang's subsidiary plans to issue warrants to incentivize its core team [36] Group 12 - Zhuoshengwei expects a net loss of 255-295 million yuan for 2025 [37] - Pingtan Development anticipates a loss for the 2025 fiscal year [38] - Nanjing Bank's major shareholder increased its stake by 123.472 million shares [39] Group 13 - Jingao Technology expects a net loss of 4.5-4.8 billion yuan for 2025 [40] - Mingyang Smart plans to acquire control of Dehua Company, with stock suspension [41] - Vanadium Titanium Co. anticipates a loss for the 2025 fiscal year [42][43] Group 14 - Tianzhihang announced a delay in its "Smart Medical Center Construction Project" [44]

Group 1 - US stock market showed slight gains with the Dow Jones up 0.17%, Nasdaq up 0.26%, and S&P 500 up 0.16%, with both Dow and S&P reaching new closing highs [3] - Major tech stocks had mixed performance, with Oracle up 3.1%, Google up 1.1%, and Tesla up 0.9%, while Meta and Intel saw declines of 1.7% and 3.1% respectively [3] - Financial sector declined over 1%, led by a drop in major banks following President Trump's announcement of a 10% cap on credit card interest rates starting January 20 [3] Group 2 - Precious metal prices surged due to risk aversion, with COMEX gold futures rising 2.54% to $4604.30 per ounce and silver futures up 7.26% to $84.61 per ounce [4] - Industrial metals also saw a rebound, with copper prices returning to $6 per pound and other metals like aluminum and nickel increasing by over 1% [4] Group 3 - Guizhou Moutai has set contract prices for some products for 2026, with significant price reductions for various types of Moutai liquor, including a drop from 2969 yuan to 1859 yuan per bottle for premium Moutai [8] - The company is adjusting its pricing strategy in response to market conditions, which may impact its revenue and profitability [8] Group 4 - The commercial aerospace sector remains active, with multiple stocks experiencing significant movements, although some companies clarified they are not involved in commercial aerospace [9] - Companies like North Navigation and Aerospace Changfeng have issued announcements regarding their business layouts in response to market interest [9] Group 5 - The market liquidity is currently abundant, and thematic trading is expected to continue, indicating a positive outlook for certain sectors [11] - Analysts suggest that the cross-year market trend may continue, although there is an increased risk of short-term technical corrections [10]

1月12日晚，万邦德（002082）和海翔药业（002099）双双发布公告，双方同意围绕渐冻症适应症，发 挥各自优势，开展相关合作。 公告显示，1月12日，万邦德全资子公司万邦德制药集团有限公司(下称"万邦德制药")与海翔药业签订 了《创新药合作协议》，致力于通过本次合作，高效推进WP205产品(渐冻症适应症，下同)的研发，最 终实现该产品在全球主要医药市场(包括但不限于中国、美国、日本等)获得用于治疗渐冻症的监管批准 并成功商业化。 双方初期合作，将聚焦于万邦德制药已获孤儿药认定的WP205产品研发和商业化，后续双方还将就万邦 德制药针对melanocortinreceptor(MCR)靶点的小分子环肽激动剂开展原料与制剂等方面的合作。 万邦德制药主要从事现代中药、化学原料药及化学制剂的研发、生产和销售。在治疗肌萎缩侧索硬化 (下称"ALS"，也称渐冻症)领域，万邦德制药布局了自主研发项目WP205产品，已获得美国FDA针对渐 冻症的孤儿药认定(申请号为DRU-2024-10575)，并申报相关制剂专利。此外，该公司还布局了针对 melanocortinreceptor(MCR)靶点的小分子环肽激动剂，矢志 ...

Core Viewpoint - Zhejiang Haixiang Pharmaceutical Co., Ltd. has signed an innovative drug cooperation agreement with Wanbangde Pharmaceutical Holdings Group's wholly-owned subsidiary, focusing on the development and commercialization of WP205 for ALS, with plans to expand into MCR-targeted small molecule peptide agonists [1][2]. Cooperation Agreement Details - Haixiang Pharmaceutical will provide a total of 150 million yuan in funding to Wanbangde Pharmaceutical in two phases: 120 million yuan (80%) within five working days of signing, and 30 million yuan (20%) after reaching an agreement with the FDA on the Phase III clinical plan or obtaining conditional market approval in China and the U.S. [1] - In return for its investment, Haixiang will receive 15% of the global commercialization profits from WP205, including 15% of net profits from product sales and third-party licensing [1]. - The agreement includes risk control clauses, allowing Haixiang to terminate the agreement if the Phase III clinical plan is not agreed upon by June 30, 2027, with a full refund of payments plus a 3% annual usage fee [1]. Market Context - ALS has a global average incidence rate of approximately 4.42 cases per 100,000 people, with an average survival period of 3-5 years post-diagnosis, indicating significant unmet clinical needs [2]. - In the U.S., the incidence rate is reported at 4.4 cases per 100,000, highlighting a substantial untapped market potential [2]. Strategic Significance - This collaboration will enhance Haixiang's positioning in the peptide drug sector, leveraging a funding cooperation model to participate in the innovative drug development for neurodegenerative diseases, creating a complementary advantage between industry and research [2]. - The agreement does not constitute a related party transaction or a major asset restructuring, thus not requiring approval from Haixiang's board or shareholders [3].

Group 1 - The core viewpoint of the article is that Wanbangde Pharmaceutical Group has entered into a strategic partnership with Zhejiang Haixiang Pharmaceutical to advance the development and commercialization of the WP205 product, aimed at treating amyotrophic lateral sclerosis (ALS) [1] - The collaboration is formalized through an "Innovative Drug Cooperation Agreement" signed on January 12, 2026, focusing on leveraging each company's strengths for mutual development and strategic win-win outcomes [1] - The initial phase of the partnership will concentrate on the research and commercialization of the WP205 product, which has already received orphan drug designation, with a total investment of 150 million RMB [1] Group 2 - The agreement also includes future collaboration on small molecule cyclic peptide agonists targeting melanocortin receptors (MCR), covering aspects such as raw materials and formulations [1]